Sub-system
The container is part of the product. Glass that does not shed particles, an elastomer stopper that seals for years without leaching anything, a syringe or pen that a patient can use — each is qualified with the drug it holds, and device assembly has been the binding constraint on some of the most demanded medicines in recent memory.
In one sentence
Primary packaging is the set of components in direct contact with a drug product — vials, stoppers, seals, prefilled syringes, cartridges and the injection devices built around them — qualified with the formulation they contain.
Glass has to resist attack by the formulation, which can leach ions from the surface or, in the worst case, flake off thin lamellae into the product. Elastomer stoppers must seal through freezing and shipping without extractables migrating into the drug, and are coated to reduce that risk. Both are qualified per product, which is why a shortage cannot be met by buying an equivalent-looking component.
Devices raised the difficulty. A prefilled syringe or an injection pen is an assembly with mechanical tolerances, a needle, a spring and a moulded body, and it has to work first time in a patient's hand. Building and validating that assembly capacity takes years, and it — not the drug substance — is what limited supply of the most demanded injectables of recent years.
Split by material and manufacturing discipline: glass forming, elastomer moulding, and mechanical device assembly.
Anything that can migrate from a component into the drug must be identified and shown safe at the levels present, per formulation and per storage condition. It is the same discipline applied to single-use bioprocess plastics one page over, and it is the reason component substitution is a study rather than a purchase.
An injection device is assessed as a combination product: the drug, the container and the delivery mechanism together, including whether patients can use it correctly. That adds human factors studies and device regulation on top of the pharmaceutical filing, and it is a large part of why device capacity took so long to expand.
2 of these are marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
Anything that can migrate from glass or elastomer into the drug has to be identified and shown safe at the levels present, per formulation and per storage condition.
The evidence behind a component qualification is mass spectrometry, and so is the investigation when a particle turns up in a vial.
Analytical instrumentsA pen or prefilled syringe is assessed as drug, container and device together, including whether patients can use it, which is much of why device capacity took so long to approve.
Regulatory approvalDevice assembly runs on dedicated validated lines built around specific tooling, which is multi-year capital rather than something bought in when demand arrives.
Other pages in this map that name Primary packaging as something they cannot do without.
Every company named on a step below this page, ordered by how many of those steps it appears at. Compiled from the pages themselves rather than written separately, so the two cannot disagree. Not a ranking and not a recommendation.
5 more companies appear at a single step each; they are named on the pages for those steps.
Whether device assembly capacity catches up with demand for self-administered injectables.
Whether glass and stopper supply keeps pace with fill capacity additions.
Whether alternative container materials are qualified for more products.
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.